

1 **Varying magnesium concentration elicits changes in inflammatory response in human**
2 **umbilical vein endothelial cells (HUVECs)**

3 Lujain A. Almousa^{1,2}, Andrew M. Salter², and Simon C. Langley-Evans^{2*}

4 ¹ Department of Nutrition and Food Science, Princess Nora Bint Abdulrahman University,
5 Kingdom of Saudi Arabia and ² Division of Nutritional Sciences, School of Biosciences, The
6 University of Nottingham, United Kingdom

7

8 * Corresponding author:

9 SC Langley-Evans

10 School of Biosciences

11 University of Nottingham

12 Sutton Bonington Campus

13 Loughborough

14 LE12 5RD

15 United Kingdom

16 Email: Simon.Langley-Evans@nottingham.ac.uk

17

18 Short running title: Mg and expression of NF- κ B

19 Key words: Magnesium, endothelial cell, inflammation, nuclear factor kappa-light-chain-
20 enhancer of activated B cells, toll-like receptors

21

22 **Abstract**

23 The aims of this study were to determine whether low concentrations of magnesium *in vitro*
24 exacerbated the human umbilical vein endothelial cell (HUVEC) response to inflammatory
25 challenge, and whether **expression** of the nuclear factor kappa-light-chain-enhancer of
26 activated B cells (NF- κ B) through the toll-like receptor 4 (TLR4) played a role in this process.
27 HUVECs were incubated with different concentrations of Mg (low- 0.1mM, control- 1mM,
28 high- 5mM) for 72 h before being stimulated with bacterial lipopolysaccharide (LPS) for 4 h.
29 The response of cells to LPS was greater in cells cultured in low Mg, relative to control cells
30 and suppressed in high Mg. Expression of NF- κ B was increased in low-Mg and decreased with
31 high Mg. Low Mg increased the expression of TLR4 mRNA, but only in the presence of LPS.
32 Antibody blockade of TLR4 but not TLR2 blunted the response of cells to LPS in low Mg, such
33 that they were similar to unblocked 1mM Mg cells. Associations of Mg with cardiovascular
34 disease may therefore relate to inflammatory responses mediated through the TLR4/NF- κ B
35 pathway.

36

37 **Introduction**

38 Magnesium (Mg) is fundamental to endothelial cell function [1] and several studies have drawn
39 attention to the interaction of Mg with ATP and its influence on the biochemical functions of
40 nucleic acids, enzymes, phospholipids, and proteins [1-4]. Endothelial dysfunction associated
41 with inflammation is a key stage in atherosclerosis [5]. Mg **undernutrition and deficiency**,
42 which some studies have associated with cardiovascular disease [6, 7], has been proposed to
43 alter the function of endothelial cells by activating the potent nuclear factor kappa-light-chain-
44 enhancer of activated B cells (NF- κ B) [8]. NF- κ B activation can be triggered by a number of
45 factors, including ultraviolet (UV) radiation, reactive oxygen species, and bacterial or viral
46 products, such as lipopolysaccharides (LPS) [9].

47 The NF- κ B family comprises many members, including NF- κ B1 (p50), NF- κ B2 (p52), REL
48 proto-oncogene, NF- κ B subunit (RelA, p65), RelB, and RelC. In the cytoplasm, NF- κ B family
49 members are bound to members of the NF- κ B inhibitor (I κ B) family, which includes six
50 proteins [9, 10]. In unstimulated cells, I κ B functions as an inhibitor protein that binds to NF-
51 κ B to keep it inactive in the cytoplasm and prevent it from binding to DNA [11]. The
52 translocation of NF- κ B to the nucleus occurs when I κ B is degraded by phosphorylation by the
53 upstream I κ B kinase [12] complex [13]. The toll-like receptor (TLR) transmembrane family
54 plays a role in identifying pathogens and eliciting the innate immune response. Toll-like
55 receptor 4 (TLR4) is activated in response to LPS and induces the activation of the NF- κ B
56 pathway [14, 15]. When LPS binds to endothelial TLR4, it activates the downstream signal for
57 these receptors via the myeloid differentiation protein 88 (MyD88) toll-domain containing
58 protein, which phosphorylates the interleukin-1 (IL-1) receptor-associated kinase-1 (IRAK1).
59 This, in turn, activates the tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6)
60 [16]. This upstream activation results in a release of NF- κ B from the I κ B cytoplasmic inhibitor,
61 [17]. In the presence of LPS, TLR4 expression can result in NF- κ B activation via the mitogen-

62 activated protein kinase (MAPK) pathway [18], which in turn activates p38 MAPK and c-Jun
63 N-terminal kinase (JNK) [19].

64 Whilst NF- κ B has been previously identified as being responsive to Mg deficiency, there has
65 not been a full evaluation of magnesium effects on the NF- κ B cascade and toll-like receptor
66 signalling. This study aimed to investigate the effect of Mg on the NF- κ B pathway in basal
67 conditions and in the presence of LPS.

68 **Methods and Materials**

69 **Cell Culture**

70 Primary HUVECs (C2519A; Lonza Basel, Switzerland) were cultured in endothelial cell
71 growth medium (EGM-2, Lonza) with 2% foetal bovine serum (FBS). The HUVEC cultures
72 were incubated in six well plates at seed density ($7500/\text{cm}^2$), at 37°C (5% CO_2), with medium
73 changed every other day until the cells were grown to 80–90% confluence. At 80% confluence,
74 the HUVECs were cultured in human endothelial Mg-free medium (Invitrogen, USA)
75 supplemented with 10% FBS, 1% penicillin 100 \times 1%, 5% endothelial cell growth supplement
76 (Sigma-Aldrich, UK), and MgSO_4 concentrations of 0.1 mM and 5 mM following the method
77 of Ferre *et al.*, and Maier *et al.*, [1, 20]. The samples were compared with cells cultured with
78 1 mM MgSO_4 , which is the physiological circulating concentration of Mg. After 3 days, the
79 cells were treated for 4 h with 0.5 $\mu\text{g}/\text{mL}$ LPS (*Salmonella enterica* serotype Enteritidis, Sigma-
80 Aldrich) and the response was compared with untreated cells. HUVECs were plated onto six-
81 well plates, and the cells were treated with 0.1 mM, 1 mM or 5 mM MgSO_4 for 3 day. Next,
82 the cells were blocked for 30 minutes using 10 $\mu\text{g}/\text{mL}$ neutralising antibodies (Anti-TLR-2 or
83 Anti-TLR-4; InvivoGen, USA) [21], Anti-TLR2 and Anti-TLR4 together; some cells were not
84 blocked and were used as a control. The cells were then stimulated with 0.5 $\mu\text{g}/\text{mL}$ LPS for 4

85 h. Culture media were collected for ELISA, and cells were collected to measure the amount of
86 cellular protein. In a separate experiment, cells were collected for gene expression analysis.

87

88 **RNA Extraction and Measurement of mRNA by qRT-PCR**

89 RNA was extracted from the HUVECs using a High Pure RNA Isolation Kit (Roche,
90 Mannheim, Germany) according to the manufacturer's protocol. Single-stranded cDNA was
91 synthesised using a RevertAid Reverse Transcription Kit (ThermoFisher Scientific, USA)
92 following the manufacturer's instructions. A Thermo Scientific Nano Drop ND-1000
93 spectrophotometer (Thermo Scientific, Wilmington, USA) was used to quantify and determine
94 RNA concentrations. RNA integrity was also tested by denaturing gel electrophoresis and
95 running an aliquot of the RNA sample on an agarose gel (1% agarose gel was dissolved in 100
96 ml 1x TAE buffer) stained with ethidium bromide. Primer Express Software v3.0 (Applied
97 Biosystems, USA) was used to design the primers for quantitative real-time polymerase chain
98 reaction (qRT-PCR). All sequences were taken from the National Centre for Biotechnology
99 Information (NCBI). The design of the primers was confirmed using the Basic Local
100 Alignment Search Tool (BLAST). Quantification of mRNA was performed as previously
101 described. The forward and reverse primer pairs are listed as in Table 1. A LightCycler 480
102 (Roche) was used to perform Quantitative Real-Time Polymerase Chain Reaction qRT-PCR.
103 The method involved a cycling state of 95°C for 5 min, then 45 cycles for 10 s at 95°C, followed
104 by an annealing for 15 seconds at 60 °C and elongation step for 15 seconds at 72°C. Using a
105 SYBR Green Master Mix. All values were normalised to the cyclophilin B housekeeping gene
106 [22]. Using this method, a relative quantification of gene expression can be calculated using a
107 mathematical model known as the comparative threshold ($2^{-\Delta\Delta ct}$) [23]. Expression of

108 cyclophilin B was not significantly influenced by either LPS treatment or variation in Mg
109 concentration.

110 **NFκB Pathway Array**

111 A Human NFκB Pathway Array kit (R&D Systems, Ltd.) was used to quantify the expression
112 of the proteins involved in the NFκB pathway. The array uses captured antibodies spotted on a
113 nitrocellulose membrane. HUVECs were plated onto six-well plates, and the cells were
114 stimulated with 0.5 μg/mL LPS for 4 h. At the end of the stimulation period, the cells were
115 washed with cold PBS, and then 120 μl lysis Buffer RIPA (radio-immunoprecipitation assay)
116 buffer (Sigma Aldrich, UK) was added with 5 μl/ml of protease inhibitor cocktail (Calbiochem,
117 USA). The plate was incubated on ice for 30 minutes. Cells were harvested and the array
118 membrane was blocked according to the manufacturer's instructions (Human NFκB Pathway
119 Array kit; R&D Systems, Ltd.). The spot signal densities were analysed using Quantity One
120 Analysis Software (Bio-Rad).

121 **Enzyme-linked Immunosorbent Assay (ELISA)**

122 The Human CXCL8/IL-8 Quantikine Immunoassay kit and the Human VCAM-1 DuoSet kit
123 (R&D Systems, Ltd.) is a quantitative sandwich enzyme immunoassay microplate-based
124 technique. These kits were used to measure interleukin-8 (IL-8) and vascular cell adhesion
125 molecule-1 (VACM-1) in cell culture supernatants. For both assays, a microplate was
126 precoated with analyte of interest monoclonal antibody, which bonded with a target analyte in
127 the samples. Detection of the bound to the primary antibody was assessed through the addition
128 of a second horseradish peroxidase antibody and the addition of reagent to produce a coloured
129 reactant that can be determined by spectrophotometry.

130

131

132 **Statistical Analyses**

133 Each treatment group comprised four samples with a sample being a single well on a culture
134 plate. All data are presented as mean \pm standard error of mean [24]; the mRNA expression data
135 were analysed using a two-way analysis of variance (ANOVA; SPSS Statistics 22 software).
136 Data with $p < 0.05$ were regarded as statistically significant. Statistical significance between
137 treatment groups was determined using Dunnett's test as a post-hoc test for the effect of Mg
138 (using 1mM Mg as the control condition) and for the effect of LPS. Protein expression were
139 analysed using a one-way analysis of variance (ANOVA; SPSS Statistics 22 software).

140 **Results**

141 To determine the effect of Mg on the mRNA expression of genes involved in the NF- κ B
142 pathway, LPS was used to stimulate the HUVECs in the presence of varying Mg
143 concentrations. As shown in Figure 1A HUVECs expressed TLR4, and there was significant
144 effect of magnesium concentration and LPS on TLR4 mRNA expression ($P = 0.001$ for
145 magnesium concentration \times LPS interaction), and a low concentration of magnesium markedly
146 increased the TLR-4 mRNA relative to the physiological concentration of magnesium 1 mM,
147 in the presence of LPS. At the low Mg concentration, the expression of IRAK1, TRAF6 and
148 I κ B mRNA expression was not significantly different from the control. Although the impact
149 of LPS on expression of these genes tended to be greater in Mg deficient cells, this was not
150 statistically significant (Figure 1).

151 As shown in Figure 1 E a significant increase in NF- κ B2 mRNA was observed in the
152 magnesium-deficient cells that were stimulated with LPS ($P=0.032$, Dunnett test), Moreover,
153 a marked decreased in NF- κ B2 mRNA in the high-magnesium LPS-stimulated HUVECs was
154 observed ($P=0.048$, Dunnett test) relative to the 1 mM physiological concentration. Mg
155 concentration had no significant effect on JUN and C-JUN mRNA (Figure 1 F and G).

156 In an attempt to gain more detailed understanding of the NF- κ B pathway's response to Mg,
157 HUVECs were treated with LPS (0.5 μ g/ml) for 4 hours. Protein extraction was performed and
158 concentration of proteins in the pathway was assessed using an NF- κ B array kit. The array
159 considered expression of 41 proteins, but for this analysis we focused on the 11 proteins
160 involved in inflammatory processes TLR-2, MYD88, TRAF2, IRAK1 Ikk α , Ikk β , Ikk γ , Ikb α ,
161 Ikb ϵ , JNK1/2, JUN2. Under LPS stimulation, there were no significant effects of either low
162 or high Mg upon concentration of TLR2, MyD88, TRAF3, IRAK1, JNK1/2 and JUN2 proteins,
163 consistent with the mRNA analyses for JUN, IRAK and TRAF2 (Table 2). Protein expression
164 of the components of the MyD88-independent pathway was not altered by varying Mg
165 concentration (Ikk α , Ikk β , Ikk γ , Ikb α and Ikb ϵ ; Table 2).

166 To investigate the role of toll-like receptors in mediating the effects of Mg on the response to
167 LPS challenge, we repeated experiments in the presence of antibodies to block TLR2 and
168 TLR4. The effects of the treatments on mRNA expression of NF- κ B, intercellular cell adhesion
169 molecule (ICAM1) and VCAM1 were generally similar (Figure 2). Blocking LPS-stimulated
170 HUVECs with anti-TLR-2, anti-TLR-4 and both anti-TLR-2+TLR-4 antibodies significantly
171 decreased the mRNA expression in cells cultured in 0.1 mM Mg or 1mM Mg, when compared
172 to LPS treatment alone at the same magnesium concentration. As expected, a high magnesium
173 concentration (5 mM) markedly reduced expression of mRNA in LPS-stimulated HUVECs
174 compared to the HUVECs cultured in 1 mM MgSO₄ of the same treatment group. No effect of
175 antibody blockade was noted in cells cultured in high magnesium. The effects of antibody
176 blockade were greater with anti-TLR4 than anti-TLR2, suggesting that the former was the
177 major mediator of LPS-stimulated effects on expression of these genes. Similar effects were
178 noted in the analysis of IL-8, IL-6 and monocyte chemoattractant protein-1 (MCP-1) mRNA
179 expression (Figure 2). However, unlike the observations for NF- κ B, ICAM1 and VCAM1, anti

180 TLR-4 blockade of cells cultured in high Mg resulted in further suppression of expression for
181 IL-8 and MCP-1 ($P<0.05$).

182 To confirm that mRNA expression effects were also present at the protein level, VCAM-1 and
183 IL-8 concentrations were determined by ELISA. The results, as shown in Figure 3 A,
184 demonstrated that magnesium concentration and blocker had a significant interactive effect
185 ($P< 0.001$) on the protein concentration of IL-8. Low magnesium considerably increased
186 secretion of IL-8 by stimulated HUVECs, compared to 1 mM MgSO₄ in the same treatment
187 groups. In addition, the blocking HUVECs with anti-TLR-4 antibody decreased IL-8 protein
188 concentration markedly compared to the LPS treated cells, but anti TLR-2 had the opposite
189 effect. Figure 3 B shows that there was a significant effect of magnesium concentration ($P<$
190 0.001), and the antibody blockade on VCAM-1 expression ($P< 0.001$).

191

192 Discussion

193 Under normal circumstances endothelial cells produce I κ B, which inhibits NF- κ B subunit
194 activity, but in endothelial dysfunction, NF- κ B is activated via the degradation of I κ B by
195 proteasomes, generally in response to inflammatory signals [25]. This results in release of
196 activated NF- κ B subunits p50 and p65, which then translocate to the nucleus leading to
197 transcription of inflammatory genes [9, 17]. The TLR-4 signalling pathway plays a key role in
198 inducing the NF- κ B pathway [26]. As hypothesised, the results of the present study confirmed
199 that HUVECs cultured in a medium with a low concentration of Mg for 72 hours significantly
200 increased NF- κ B mRNA expression, as measured by qRT-PCR. In contrast, HUVECs treated
201 with 5mM Mg showed a reduced expression of NF- κ B. Other studies have reported that TNF
202 stimulation of HUVECs upregulated the gene expression of NF- κ B and I κ B [13]. Our findings
203 are consistent with this and with other studies that showed HUVECs cultured in a medium with

204 a low Mg concentration (0.1 mM) had an enhanced NF-κB activity, which was further
205 increased after treatment with 1 μg/mL LPS [8]. However, we did not observe widespread
206 changes in expression of components of the NF-κB pathway and Mg appeared to have
207 relatively selective effects on NF-κB2.

208 The novel element of this study was the investigation of the role of toll-like receptors in
209 mediating Mg-related effects on inflammatory responses in HUVECs. Cells cultured with a
210 low concentration of Mg and challenged with LPS showed a significant increase in the
211 expression of TLR4. Other studies have shown that endothelial cells expressed TLR4 to
212 activate NF-κB in response to LPS exposure [16, 27]. Many researchers have noted that LPS
213 activates NF-κB in HUVECs via TLR4 and MyD88 [28, 29]. Similarly, TLR4, MyD88, and
214 TRAF have been reported to be upregulated after HUVECs were treated with 100 ng/mL LPS
215 [30]. However, the present study found no difference in the gene expression of IRAK1,
216 TRAF6, IκB, MyD88, Iκk, and IκB proteins in the NF-κB pathway in response to varying Mg
217 concentration. Additionally, incubation at different magnesium concentrations did not
218 significantly affect the expression of c-Jun and Jun.

219 One of the main limitations of the present study is that measurements focused on the effects of
220 varying magnesium concentration and LPS treatment upon expression of key targets at the
221 mRNA and protein level only. Functional activity of the NF-κB pathway is critically
222 determined by post-translational modification of proteins and translocation within the cell.
223 These modifications at the protein level were not studied and would be a high priority for
224 further studies that can categorically determine the involvement of the pathway in magnesium
225 concentration-dependent modulation of the inflammatory response.

226 Most current research focuses on the role of TLR4 in eliciting the response of HUVECs to
227 LPS. TLR2 has also been implicated in the LPS pathway, but no study has previously
228 investigated the effect of blocking TLR-2 on NF-κB activation in HUVECs. Our results

229 confirm the hypothesis that TLR-4 and, to a lesser extent, TLR-2 play a role in regulation of
230 NF- κ B activation, as blocking these receptors significantly inhibited the effect of LPS on NF-
231 κ B translocation and activation in the HUVECs cultured in a low Mg concentration. This
232 showed that Mg deficiency can influence processes which depend on both receptors. These
233 results are consistent with those reported by [31], which indicated that blocking TLR-4 in
234 HUVECs inhibits the effect of LPS in activating NF- κ B. Similarly, blocking TLR-4 in human
235 dermal microvascular endothelial cells (HMEC) stimulated with LPS results in inhibition of
236 NF- κ B activity [27].

237 Interestingly, the high magnesium concentration was shown to inhibit the response to LPS
238 more efficiently than anti-TLR-2 and anti-TLR-4 antibodies. Magnesium appears to have a
239 direct impact the TLR-4 receptors, based on the fact that magnesium does not modify the
240 expression of MyD88 and, subsequently, TRAF6. The anti-inflammatory impact of magnesium
241 in the TLR-LPS pathway may occur via several mechanisms. Firstly magnesium can directly
242 inhibit the LPS induced expression of the TLR-4 receptor (as confirmed in this study) and
243 therefore limit NF- κ B activation. Additionally, magnesium acts as a calcium channel blocker
244 and effect on the intracellular calcium concentration [32, 33]. Calcium is a major promoter of
245 inflammation [34, 35] due to its role in the activation of the TLR-4 receptors [36]. Finally high
246 magnesium blocks the NMDA receptors, which regulate the pre-inflammatory response [37,
247 38]. Such blocking leads to reduced activity of the TLR-4 receptor, and magnesium has an
248 antagonistic effect on the NMDA receptor [39]. Mg²⁺ can suppress NMDA receptors through
249 a voltage dependent manner [38].

250 Another substantial finding of this study is that a high magnesium concentration significantly
251 inhibits the expression of the adhesion molecules; ICAM-1 and VCAM-1 in LPS-stimulated
252 HUVECs. TLR-2 and TLR-4 play a significant role in ICAM-1 and VCAM-1 release, and the
253 blocking of these receptors also significantly downregulated the expression of ICAM-1 and

254 VCAM-1 when cells were exposed to a low magnesium concentration. The results of the
255 present study agree with the findings reported by Nakamura et al. [40] who found that
256 incubating stimulated HUVECs with anti-TLR-2 and anti-TLR-4 antibodies significantly
257 inhibited mononuclear cell adhesion to the HUVEC's surface.

258 One of the main findings of this study was that inhibition of TLR-4 by neutralising antibodies
259 in stimulated HUVECs, cultured in a low magnesium concentration, decreased the LPS
260 induced expression of the inflammatory cytokines IL-8, IL-6 and MCP-1 mRNA. Moreover,
261 this inhibitory effect of the antibodies was enhanced with exposure to a high magnesium
262 concentration. The addition of magnesium significantly inhibited the release of IL-8, IL-6 and
263 MCP-1 in cells following LPS treatment. These results are consistent with the findings reported
264 by Hippenstiel et al. [41], who clarified that activated NF- κ B was important in upregulating
265 IL-8 expression and that IL-8 expression was inhibited in LPS-stimulated HUVECs when Rho
266 was blocked. The work of Masood et al. [42] also indicated that, after stimulating HUVECs
267 with the serum of patients with bacterial infections and incubating them with TLR antibodies,
268 blockade with anti-TLR-4 markedly decreased the expression of IL-8 by 40%, whereas
269 blockade with anti-TLR-2 only slightly decreased the expression of IL-8. The present study
270 similarly found that the effects of TLR-4 blockade were greater than seen with TLR-2
271 blockade. Shimamoto et al. [43] observed that the TLR-4 mutation in mice inhibited the
272 expression of IL-6 and MCP-1 mRNA in the animals' hearts. Furthermore, incubating
273 HUVECs with siRNA to silence TLR-4 for 24 hours, then stimulating them with LPS
274 significantly decreased the expression of MCP-1 [44].

275 The relevance of this in vitro study to human health needs to be considered in the context of
276 magnesium intake, particularly as a number of studies have identified relationships between
277 intake and cardiovascular disease risk [6, 7, 45, 46]. Magnesium nutrition is often overlooked,
278 but low intakes are commonplace in Western populations. The data presented in this paper

279 demonstrate that the inflammatory response of HUVECs to bacterial endotoxin is exacerbated
280 by low Mg concentrations in vitro, but suppressed with high Mg. Toll-like receptors and the
281 NF- κ B pathway may be central to these effects.

282

283 **Acknowledgements**

284 This study was funded by the Princess Nora bint Abdulrahman University, Saudi Arabia. The
285 authors have no conflict of interest to declare.

286

- 288 1. Ferrè S, Mazur A, Maier JA. Low-magnesium induces senescent features in cultured human
289 endothelial cells. *Magnesium research*. 2007;20(1):66-71.
- 290 2. Wolf FI, Trapani V. Cell (patho) physiology of magnesium. *Clinical science*. 2008;114(1):27-
291 35.
- 292 3. Bernardini D, Nasulewicz A, Mazur A, Maier J. Magnesium and microvascular endothelial
293 cells: a role in inflammation and angiogenesis. *Front Biosci*. 2005;10:1177-82.
- 294 4. Maier JA. Low magnesium and atherosclerosis: an evidence-based link. *Molecular aspects of*
295 *medicine*. 2003;24(1):137-46.
- 296 5. Maier JA. Endothelial cells and magnesium: implications in atherosclerosis. *Clinical science*.
297 2012;122(9):397-407.
- 298 6. Swaminathan R. Magnesium metabolism and its disorders. *The Clinical Biochemist Reviews*.
299 2003;24(2):47.
- 300 7. Champagne CM. Magnesium in hypertension, cardiovascular disease, metabolic syndrome,
301 and other conditions: a review. *Nutrition in Clinical Practice*. 2008;23(2):142-51.
- 302 8. Ferrè S, Baldoli E, Leidi M, Maier JA. Magnesium deficiency promotes a pro-atherogenic
303 phenotype in cultured human endothelial cells via activation of NFkB. *Biochimica et Biophysica Acta*
304 *(BBA)-Molecular Basis of Disease*. 2010;1802(11):952-8.
- 305 9. Valen G, Yan Z-q, Hansson GK. Nuclear factor kappa-B and the heart. *Journal of the American*
306 *College of Cardiology*. 2001;38(2):307-14.
- 307 10. Savinova OV, Hoffmann A, Ghosh G. The Nfkb1 and Nfkb2 proteins p105 and p100 function
308 as the core of high-molecular-weight heterogeneous complexes. *Molecular cell*. 2009;34(5):591-602.
- 309 11. Berg A, Baldwin A. The Ikb proteins: multifunctional regulators of rel/NFk-B transcription.
310 *Genes Dev*. 1993;7:2064-70.
- 311 12. Saris N-EL, Mervaala E, Karppanen H, Khawaja JA, Lewenstam A. Magnesium: an update on
312 physiological, clinical and analytical aspects. *Clinica chimica acta*. 2000;294(1):1-26.
- 313 13. Perrot-Appanat M, Vacher S, Toullec A, Pelaez I, Velasco G, Cormier F, et al. Similar NF-kB
314 gene signatures in TNF- α treated human endothelial cells and breast tumor biopsies. *PLoS One*.
315 2011;6(7):e21589.
- 316 14. Chong AJ, Shimamoto A, Hampton CR, Takayama H, Spring DJ, Rothnie CL, et al. Toll-like
317 receptor 4 mediates ischemia/reperfusion injury of the heart. *The Journal of thoracic and*
318 *cardiovascular surgery*. 2004;128(2):170-9.
- 319 15. Zhang G, Ghosh S. Toll-like receptor-mediated NF-kB activation: a phylogenetically
320 conserved paradigm in innate immunity. *The Journal of clinical investigation*. 2001;107(1):13-9.
- 321 16. Zen K, Karsan A, Stempien-Otero A, Yee E, Tupper J, Li X, et al. NF-kB activation is required
322 for human endothelial survival during exposure to tumor necrosis factor- α but not to interleukin-1 β
323 or lipopolysaccharide. *Journal of Biological Chemistry*. 1999;274(40):28808-15.
- 324 17. Sun Z, Andersson R. NF-kB activation and inhibition: a review. *Shock*. 2002;18(2):99-106.
- 325 18. Yang Y, Zhou H, Yang Y, Li W, Zhou M, Zeng Z, et al. Lipopolysaccharide (LPS) regulates TLR4
326 signal transduction in nasopharynx epithelial cell line 5-8F via NFkB and MAPKs signaling pathways.
327 *Molecular immunology*. 2007;44(5):984-92.
- 328 19. Manna SK, Ramesh GT. Interleukin-8 induces nuclear transcription factor-kB through a
329 TRAF6-dependent pathway. *Journal of Biological Chemistry*. 2005;280(8):7010-21.
- 330 20. Maier JA, Malpuech-Brugère C, Zimowska W, Rayssiguier Y, Mazur A. Low magnesium
331 promotes endothelial cell dysfunction: implications for atherosclerosis, inflammation and
332 thrombosis. *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease*. 2004;1689(1):13-21.
- 333 21. Satta N, Kruihof EK, Fickentscher C, Dunoyer-Geindre S, Boehlen F, Reber G, et al. Toll-like
334 receptor 2 mediates the activation of human monocytes and endothelial cells by antiphospholipid
335 antibodies. *Blood*. 2011;117(20):5523-31.

- 336 22. Daniel ZC, Akyol A, McMullen S, Langley-Evans SC. Exposure of neonatal rats to maternal
337 cafeteria feeding during suckling alters hepatic gene expression and DNA methylation in the insulin
338 signalling pathway. *Genes & nutrition*. 2013;9(1):365.
- 339 23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time
340 quantitative PCR and the 2- $\Delta\Delta$ CT method. *methods*. 2001;25(4):402-8.
- 341 24. Yee NS, Kazi AA, Yee RK. Cellular and developmental biology of TRPM7 channel-kinase:
342 implicated roles in cancer. *Cells*. 2014;3(3):751-77.
- 343 25. Collins T, Read MA, Neish AS, Whitley M, Thanos D, Maniatis T. Transcriptional regulation of
344 endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. *The FASEB*
345 *Journal*. 1995;9(10):899-909.
- 346 26. Olivieri F, Rippo MR, Prattichizzo F, Babini L, Graciotti L, Recchioni R, et al. Toll like receptor
347 signaling in "inflammaging": microRNA as new players. *Immunity & Ageing*. 2013;10(1):11.
- 348 27. Faure E, Thomas L, Xu H, Medvedev AE, Equils O, Arditi M. Bacterial lipopolysaccharide and
349 IFN- γ induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role
350 of NF- κ B activation. *The Journal of Immunology*. 2001;166(3):2018-24.
- 351 28. He W, Qu T, Yu Q, Wang Z, Lv H, Zhang J, et al. LPS induces IL-8 expression through TLR4,
352 MyD88, NF-kappaB and MAPK pathways in human dental pulp stem cells. *International endodontic*
353 *journal*. 2013;46(2):128-36.
- 354 29. Andreakos E, Sacre SM, Smith C, Lundberg A, Kiriakidis S, Stonehouse T, et al. Distinct
355 pathways of LPS-induced NF- κ B activation and cytokine production in human myeloid and
356 nonmyeloid cells defined by selective utilization of MyD88 and Mal/TIRAP. *Blood*. 2004;103(6):2229-
357 37.
- 358 30. Wang W, Deng M, Liu X, Ai W, Tang Q, Hu J. TLR4 activation induces nontolerant
359 inflammatory response in endothelial cells. *Inflammation*. 2011;34(6):509-18.
- 360 31. Guo F, Tang J, Zhou Z, Dou Y, Van Lonkhuyzen D, Gao C, et al. GEF-H1-RhoA signaling
361 pathway mediates LPS-induced NF- κ B transactivation and IL-8 synthesis in endothelial cells.
362 *Molecular immunology*. 2012;50(1):98-107.
- 363 32. Libako P, Nowacki W, Castiglioni S, Mazur A, Maier JA. Extracellular magnesium and calcium
364 blockers modulate macrophage activity. *Magnesium research*. 2016;29(1):11-21.
- 365 33. Libako P, Miller J, Nowacki W, Castiglioni S, Maier JA, Mazur A. Extracellular Mg
366 concentration and Ca blockers modulate the initial steps of the response of Th2 lymphocytes in co-
367 culture with macrophages and dendritic cells. *European cytokine network*. 2015;26(1):1-9.
- 368 34. Kupetsky-Rincon EA, Uitto J. Magnesium: novel applications in cardiovascular disease—a
369 review of the literature. *Annals of Nutrition and Metabolism*. 2012;61(2):102-10.
- 370 35. Mazur A, Maier JA, Rock E, Gueux E, Nowacki W, Rayssiguier Y. Magnesium and the
371 inflammatory response: potential physiopathological implications. *Archives of biochemistry and*
372 *biophysics*. 2007;458(1):48-56.
- 373 36. Chiang C-Y, Veckman V, Limmer K, David M. Phospholipase Cy-2 and intracellular calcium are
374 required for lipopolysaccharide-induced Toll-like receptor 4 (TLR4) endocytosis and interferon
375 regulatory factor 3 (IRF3) activation. *Journal of Biological Chemistry*. 2012;287(6):3704-9.
- 376 37. Liu Z, Zhang J, Huang X, Huang L, Li S, Wang Z. Magnesium sulfate inhibits the secretion of
377 high mobility group box 1 from lipopolysaccharide-activated RAW264. 7 macrophages in vitro.
378 *journal of surgical research*. 2013;179(1):e189-e95.
- 379 38. Weglicki WB, Mak IT, Chmielinska JJ, Tejero-Taldo MI, Komarov AM, Kramer JH. The role of
380 magnesium deficiency in cardiovascular and intestinal inflammation. *Magnesium research*.
381 2010;23(4):199-206.
- 382 39. Chen C-H, Tsai P-S, Huang C-J. Magnesium Sulfate Inhibits Activator Protein-1 Upregulation
383 in Endotoxin-activated Murine Macrophages. *Tzu Chi Medical Journal*. 2010;22(4):177-83.
- 384 40. Nakamura N, Yoshida M, Umeda M, Huang Y, Kitajima S, Inoue Y, et al. Extended exposure of
385 lipopolysaccharide fraction from *Porphyromonas gingivalis* facilitates mononuclear cell adhesion to

386 vascular endothelium via Toll-like receptor-2 dependent mechanism. *Atherosclerosis*.
387 2008;196(1):59-67.

388 41. Hippenstiel S, Soeth S, Kellas B, Fuhrmann O, Seybold J, Krüll M, et al. Rho proteins and the
389 p38-MAPK pathway are important mediators for LPS-induced interleukin-8 expression in human
390 endothelial cells. *Blood*. 2000;95(10):3044-51.

391 42. Masood R, Cai J, Tulpule A, Zheng T, Hamilton A, Sharma S, et al. Interleukin 8 is an autocrine
392 growth factor and a surrogate marker for Kaposi's sarcoma. *Clinical cancer research*. 2001;7(9):2693-
393 702.

394 43. Shimamoto A, Chong AJ, Yada M, Shomura S, Takayama H, Fleisig AJ, et al. Inhibition of Toll-
395 like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury. *Circulation*.
396 2006;114(1 suppl):I-270-I-4.

397 44. Ishikado A, Nishio Y, Yamane K, Mukose A, Morino K, Murakami Y, et al. Soy
398 phosphatidylcholine inhibited TLR4-mediated MCP-1 expression in vascular cells. *Atherosclerosis*.
399 2009;205(2):404-12.

400 45. Schechter M. Magnesium and the cardiovascular system. *Magnesium Research* 2010;23: 60-72.

401 46. Qu Z, Jin F, Hao Y, Li H, Tang T, Wang H, et . Magnesium and the risk of cardiovascular events: a
402 meta-analysis of prospective cohort studies. *PLoS ONE* 2013; 8: e57720.

403
404

405 **FIGURE LEGENDS**

406

407 **Figure 1. Effect of different concentrations of magnesium on NF-κB pathway gene expression.** Data is shown
408 as Mean±SEM for n=4. * indicates $P<0.05$, compared to 1 mM MgSO₄ in the same treatment (Dunnett's test), +
409 indicates $P<0.05$, ++ indicates $P<0.01$ compared to LPS at the same magnesium concentration (t-test).

410 **A: Expression of TLR-4 mRNA.** Two-way ANOVA showed significant interaction of magnesium concentration
411 × presence of LPS ($P=0.001$). There was a significant effect of magnesium concentration ($P=0.019$) and LPS
412 ($P=0.039$).

413 **B: Expression of IRAK1 mRNA.** Two-way ANOVA showed no significant interaction of magnesium
414 concentration × presence of LPS

415 **C: Expression of TRAF6 mRNA.** Two-way ANOVA showed no significant interaction of magnesium
416 concentration × presence of LPS.

417 **D: Expression of IKB mRNA.** Two-way ANOVA showed no significant interaction of magnesium concentration
418 × presence of LPS. There was a significant effect of LPS ($P= 0.002$).

419 **E: Expression of NF-KB 2 mRNA.** Two-way ANOVA showed no significant interaction of magnesium
420 concentration × presence of LPS. There was a significant effect of magnesium concentration ($P<0.001$) and LPS
421 ($P< 0.001$).

422 **F: Expression of JUN mRNA.** Two-way ANOVA showed no significant interaction of magnesium concentration
423 × presence of LPS. There was a significant effect of LPS ($P= 0.04$).

424 **G: Expression of C-JUN mRNA.** Two-way ANOVA showed no significant interaction of magnesium
425 concentration × presence of LPS. There was a significant effect of LPS ($P= 0.043$).

426

427 **Figure 2. Effect of different concentrations of magnesium on HUVEC gene expression when treated or not**
428 **treated with LPS and TLR antibodies.** Data are shown as mean ±SEM for n=4. * indicates $P<0.05$, ** indicates
429 $P<0.01$, *** indicates $P<0.001$ compared to 1mM MgSO₄ in same treatment (Dunnett t). + indicates $P<0.05$, ++
430 indicates $P<0.01$, +++ indicates $P<0.001$ compared to LPS at same magnesium concentration (Dunnett t).

431 **A: Expression of NF-κB mRNA.** Two-way ANOVA showed a significant interaction of magnesium × blocker
432 ($P< 0.001$). There was a significant effect of magnesium concentration ($P< 0.001$), and blocker ($P< 0.001$).

433 **B: Expression of ICAM-1 mRNA.** Two-way ANOVA showed a significant interaction of magnesium × blocker
434 ($P< 0.001$). There was a significant effect of magnesium concentration ($P< 0.001$), and blocker ($P< 0.001$).

435 **C: Expression of VCAM-1 mRNA.** Two-way ANOVA showed a significant interaction of magnesium × blocker
436 ($P < 0.001$). There was a significant effect of magnesium concentration ($P < 0.001$), and blocker ($P < 0.001$).

437 **D: Expression of IL-8 mRNA.** Two-way ANOVA showed a significant interaction of magnesium × blocker ($P <$
438 0.001). There was a significant effect of magnesium concentration ($P < 0.001$), and blocker ($P < 0.001$).

439 **E: Expression of IL-6 mRNA.** Two-way ANOVA showed a significant interaction of magnesium × blocker ($P <$
440 0.001). There was a significant effect of magnesium concentration ($P < 0.001$), and blocker ($P < 0.001$).

441 **F: Expression of MCP-1 mRNA.** Two-way ANOVA showed a significant interaction of magnesium × blocker
442 ($P = 0.005$). There was a significant effect of magnesium concentration ($P < 0.001$), and blocker ($P < 0.001$).

443

444 **Figure 3.** Effect of different concentrations of magnesium on HUVECs protein concentration treated or not with
445 LPS and TLR antibodies. Data are shown as mean \pm SEM for $n=4$. * indicates $P < 0.05$ compared to 1mM $MgSO_4$
446 in same treatment (Dunnett t). + indicates $P < 0.05$, ++ indicates $P < 0.01$ compared to LPS at same magnesium
447 concentration (Dunnett t).

448 **A: Protein concentration of IL-8.** Two-way ANOVA showed a significant interaction of magnesium × blocker
449 ($P < 0.001$). There was a significant effect of magnesium concentration ($P < 0.001$), and blocker ($P < 0.001$).

450 **B: Protein concentration of VCAM-1.** Two-way ANOVA showed no significant interaction of magnesium ×
451 blocker. There was a significant effect of magnesium concentration ($P < 0.001$), and blocker ($P < 0.001$).

452

453

454

455

Table 1. Primer sequences used for qRT-PCR

Symbol	Gene name	Foreword primer	Reverse primer
TLR4	Homo sapiens Toll-like receptor 4	GGGTCCAACACTTGTTTCAGTTAATAA	TGCATATCTAGTGCACCATGGAA
IRAK	Interleukin-1 receptor-associated kinase 1	CGCCCCTTTCCGTTTTG	GATCTTGAGCTCCTCCGAGAAG
TRAF6	TNF receptor-associated factor 6	TCAGTACTTTTGGTTGCCATGAA	AGCCTGGGCCAACATTCTC
IKB	Homo sapiens nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha	GCTGAAGAAGGAGCGGCTACT	TCGTACTCCTCGTCTTTCATGGA
NFkB	Nuclear translocation of nuclear factor kappaB	GGGATCTGCGCCGTTTCT	TCCCCATCATGTTCTTCTTAGTCA
Jun	Jun N-terminal kinase	ATGACTGCAAAGATGGAAACGA	GCTCTCGGACGGGAGGAA
C-JUN	c-Jun N-terminal kinase kinase 2	ATTGTGAAGGCGCTGTACTACCT	CGTCCAGCAGGATGTTGGA
PPI B	Cyclophilin B	GGAGATGGCACAGGAGGAAA	CGTAGTGCTTCAGTTTGAAGTTC TCA
IL-8	Interleukin 8	ACCGGAAGGAACCATCTCACT	ATCAGGAAGGCTGCCAAGAG
ICAM-1	Intercellular adhesion molecule	TCCCCCGGTATGAGATTG	GCCTGCAGTGCCCATTATG
VCAM	Vascular cell adhesion molecule	GCAAGGTTCTTAGCGTGTAC	GGCTCAAGCATGTCATATTCAC
IL-6	Interleukin 6	CCGGGAACGAAAGAGAAGCT	GCGCTTGTGGAGAAGGAGTT
MCP-1	Homo sapiens chemokine (C-C motif) ligand 2 (CCL2)	CGCCTCCAGCATGAAAGTCT	GGAATGAAGGTGGCTGCTATG

457

Table 2. Effect of different concentrations of Mg on NF- κ B pathway protein concentration.

458

Genes	0.1 mM MgSO ₄	1mM MgSO ₄	5mM MgSO ₄	<i>P</i> value 0.1mM vs 1mM	<i>P</i> value 5mM vs 1mM
TLR2	0.21 ± 0.12	0.09 ± 0.016	0.07± 0.011	0.62	0.67
MYD88	0.58± 0.29	0.3 ± 0.089	0.27 ± 0.06	0.46	0.99
TRAF2	0.67 ± 0.26	0.49 ± 0.12	0.35 ± 0.062	0.69	0.79
IRAK1	1.22 ± 0.31	1.05 ± 0.24	0.94 ± 0.17	0.85	0.94
JNK1/2	0.89 ± 0.21	0.71 ± 0.19	0.6 ± 0.09	0.7	0.87
JNK2	0.44 ± 0.25	0.22 ± 0.05	0.02 ± 0.036	0.48	0.99
IKK α	0.64 ± 0.29	0.4 ± 0.11	0.41 ± 0.062	0.74	0.99
IKK β	0.9 ± 0.36	0.58 ± 0.14	0.65 ± 0.095	0.54	0.96
IKK γ	0.78 ± 0.27	1.13 ± 0.25	0.84± 0.2	0.7	0.95
IKB α	1.4 ± 0.3	1.16 ± 0.31	1.03 ± 0.15	0.71	0.96
IKB ϵ	1.62 ± 0.24	1.54 ± 0.34	1.01 ± 0.2	0.91	0.32

459

460 Data is shown as Mean± SEM for n=4.

461

462

463

464

465

466

467





